Search Results

Repertoire® Immune Medicines announced that it has entered a multi-year strategic collaboration with Bristol Myers Squibb to develop tolerizing vaccines for up to three autoimmune diseases.

Takeda presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab in patients with persistent or chronic primary immune thrombocytopenia, a rare immune-mediated bleeding disorder.

Genialis, the RNA-biomarker company, announced a new partnership with the Pancreatic Cancer Action Network to expand the validation of the Genialis™ krasID biomarker in the pancreatic cancer histology.

ACTG today announced the opening of A5374, a phase 1/2a study evaluating the safety, tolerability, and antiviral effect of a novel combination regimen that includes therapeutic T-cell vaccines, two broadly neutralizing antibodies (bNAbs), and an immune-system boosting treatment among people living with HIV who started antiretroviral treatment (ART) during acute (early) HIV infection.

Integrated Oncology Network, LLC (“ION”), a portfolio company of Silver Oak Services Partners, LLC (“Silver Oak”), today announced the acquisition of Urology Partners, LLC.

Butterfly Network, Inc. today announced that Joseph DeVivo, President, Chief Executive Officer and Chairman will present and host one-on-one investor meetings at the Goldman Sachs 45th Annual Global Healthcare Conference.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced results from two studies of RADICAVA® (edaravone) for amyotrophic lateral sclerosis (ALS) at the European Network to Cure Amyotrophic Lateral Sclerosis (ENCALS) 2024 meeting.

OneMedNet Corporation, the leading curator of regulatory-grade Real World Data, inclusive of electronic health records, laboratory results and medical imaging, is pleased to announce a greater than five -fold expansion of its proprietary iRWD™ network and platform.

Daniel M. Geynisman, MD, is being announced as the new Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network.

Researchers at Children’s Hospital of Philadelphia (CHOP) announced the discovery of a novel immune-based biomarker that could pave the way for potential lifesaving early detection of high-grade ovarian cancer (HGOC).